What we do Lupin Ltd is a global pharmaceutical company developing and marketing branded and generic formulations, biotechnology products, and APIs across multiple therapy areas. |
Founded in 1,983 |
Market share Among top 10% globally; 3rd largest generics company in the US by prescriptions; 8th largest pharma company in India by sales. |
Problem solved Provides affordable, high-quality medicines to treat chronic and acute conditions globally, addressing healthcare accessibility and innovation in pharmaceuticals. |
Top clients or who we serve Serves patients, healthcare providers and institutions globally; B2B and B2C across India, US, Japan, Australia, Europe, Latin America, and emerging markets. |
Key management Key leaders include Vinita Gupta (CEO), Nilesh D Gupta (MD), and Ramesh Swaminathan (CFO), bringing global pharma expertise and strong leadership. |
Our journey and innovations Since 1983, expanded via acquisitions and R&D investments; pioneered inhalation, injectable, ophthalmic and biosimilar portfolios; launched digital therapeutics in 2024. |
Where we operate Operates in 100+ countries including India, USA, Japan, Europe, Latin America, South Africa, Australia, and emerging markets. |
Top products or what we offer Offers branded and generic drugs, biosimilars, inhalers, injectables, and APIs; specialties include anti-TB, cardiology, diabetology, CNS, respiratory and oncology. |
Top brands Linvas (cardiology), Gibtulio (diabetes), Xopenex and Brovana (respiratory inhalers), Namuscla (orphan drug), Rymti (biosimilar), Cialis (licensed ED product). |
Raw materials needed Pharmaceutical-grade chemicals, active pharmaceutical ingredients, biotechnology inputs, and excipients. |
Raw materials supplier Global and local suppliers meeting regulatory standards; exact suppliers confidential. |
Recurring vs cyclical contribution Revenue is predominantly recurring from generics and specialty medicines with steady demand and innovation pipeline. |
Our industry position Global leader in generics with strong US market presence, robust R&D pipeline, and expanding specialty product offerings. |
Financial highlights FY25 consolidated revenue ₹227 billion; net profit ₹33 billion; strong EBITDA margin growth (31.3% in Q2 FY26); robust cash flows. |
Geographical revenue split India 30%, USA 40%, Emerging Markets 14%, Developed Markets 12%, API 4%. |
Order book - |
Whats driving growth Growth from new product launches, specialty injectables, inhalers, biosimilars, expanding geographic presence, and operational excellence. |
Our future plans Expand specialty and biosimilar portfolio, invest in digital health, increase market share in US and India, and grow in emerging markets. |
Our green promise Targets 38% GHG reduction by 2030, commits to renewable energy, water recycling, biodiversity initiatives, and sustainable sourcing. |
Our people and values Employs approx. 20,000; emphasizes diversity, employee development, workplace safety, and ethics-driven culture. |
Key challenges ahead Regulatory compliance, competition in generics, US FDA inspections, and evolving healthcare policies globally. |
Interesting facts Launched first approved generic Spiriva in US/Canada; operates 33 subsidiaries worldwide; strong ESG leader with top sustainability ratings. |
Risks and strategy Mitigates regulatory and market risks via diversified portfolio, robust compliance, innovation investment, and strategic acquisitions. |
